Multiple Myeloma Clinical Trial
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Summary
High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant recipients worldwide for the same or similar disorders.
Full Description
Many patients with multiple myeloma receive 2 stem cell transplantations within a few months of each other as part of their treatment. Usually the drug Melphalan is used for both transplants.
Bortezomib is a drug that is used for treating multiple myeloma and has been used in combination with melphalan for stem cell transplantation for patients with multiple myeloma.
The purpose of this trial is to study the effects of doing 2 transplants, first using melphalan and second using melphalan and bortezomib. The trial is aiming to find out if adding the Bortezomib to the second transplant will increase the chances of staying in remission longer.
Eligibility Criteria
Changed from: Inclusion Criteria:
Confirmed diagnosis of multiple myeloma with either Durie-Salmon stage I, II, or III or ISS stage I, II or III, less than 12 months since initiation of systemic therapy
≥8x106 CD34+cells/kg available in cryopreservation in aliquots appropriate for tandem transplants
Age: 18-75 years at time of transplantation
KPS 70-100%
Recovery from complications of prior therapies
Gender: There is no gender restriction
Exclusion Criteria:
Diagnosis other than multiple myeloma
Chemotherapy or radiotherapy within 8 days of initiating treatment in this study
Prior autologous or allogeneic transplantation (except as enrolled into this study)
Uncontrolled bacterial, viral, fungal or parasitic infections
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Hackensack New Jersey, 07601, United States
How clear is this clinincal trial information?